Trevena, Inc. (TRVN) |
|
1.05 -0.01 (-0.94%)
|
06-09 14:26 |
|
Open: |
1.07 |
Pre. Close: |
1.06 |
|
High:
|
1.12 |
Low:
|
1.04 |
|
Volume:
|
381,341 |
Market Cap:
|
12(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 2:18:07 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.63  One year: 3.83 |
| Support: |
Support1: 0.61 Support2: 0.5 |
| Resistance: |
Resistance1: 2.26 Resistance2: 3.27 |
| Pivot: |
1.11  |
| Moving Average: |
MA(5): 1.06 MA(20): 1.14
MA(100): 1.09 MA(250): 3.47 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 30.3 %D(3): 30.4 |
| RSI: |
RSI(14): 48.3 |
| 52-week: |
High: 12.22 Low: 0.57 |
| Average Vol(K): |
3-Month: 3,009 (K) 10-Days: 1,828 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TRVN ] has closed above bottom band by 23.0%. Bollinger Bands are 70.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.1 - 1.11 |
1.11 - 1.11 |
|
Low:
|
1.04 - 1.04 |
1.04 - 1.05 |
|
Close:
|
1.05 - 1.06 |
1.06 - 1.07 |
|
Company Description |
|
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. |
Headline News |
Wed, 07 Jun 2023
Premarket Mover: Trevena Inc (TRVN) Down 3.70% - InvestorsObserver
Thu, 01 Jun 2023
Trevena Inc (TRVN) Down 5.26% in Premarket Trading - InvestorsObserver
Wed, 31 May 2023
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical - Yahoo Finance
Wed, 31 May 2023
5 Hot Penny Stocks To Watch With Big News This Week - Penny Stocks
Tue, 30 May 2023
Trevena Inc (TRVN) has fallen 2.61% Tuesday In Premarket Trading - InvestorsObserver
Wed, 24 May 2023
Should You Accumulate Trevena Inc (TRVN) Stock Wednesday Morning? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
11 (M) |
|
% Held by Insiders
|
1.087e+007 (%) |
|
% Held by Institutions
|
3.3 (%) |
|
Shares Short
|
130 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.969e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
11 |
|
Return on Assets (ttm)
|
585.1 |
|
Return on Equity (ttm)
|
-61 |
|
Qtrly Rev. Growth
|
-432000 |
|
Gross Profit (p.s.)
|
-34.15 |
|
Sales Per Share
|
-73.89 |
|
EBITDA (p.s.)
|
-1.67805e+006 |
|
Qtrly Earnings Growth
|
-5.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-44 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.02 |
|
Price to Cash Flow
|
1.91 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
752660 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
